Celltrion's manufacturing ops figure in AstraZeneca buyout buzz

A multinational pharma company may have more reason for wanting Celltrion than its biosimilar of multibillion-dollar blockbuster arthritis treatment Remicade. Rumors are swirling that AstraZeneca ($AZN) may have its sights set on the Korean biosimilars maker, and a buyout would give the British drugmaker--or any of its rivals--an established biologics plant in a strategic location, and one that's expanding, at that. Story